About

Luoyang Geneture Medical Technology CO., LTD.

Corporate Overview：

Luoyang (CHINA) Geneture Medical Technology CO., LTD. operates a 5,000 m² R&D and manufacturing facility certified as a high-tech enterprise. An innovation driver in molecular diagnostics, the company supplies intelligent diagnostic instruments, compatible reagents, and integrated solutions to medical institutions, research organizations, and public-health systems worldwide, establishing a complete “innovative R&D – in-house production – global sales” value chain; its products are deployed throughout clinical diagnostics and precision medicine.

R&D Excellence:

Our multi-disciplinary R&D enginer integrates expertise in molecular biology, biochemistry, mechanical engineering, electronics and software. The platform covers the complete molecular workflow—sample preparation, nucleic-acid extraction, real-time and digital amplification, library preparation and high-throughput sequencing. Four product families have been launched to date:

l Tumor precision detection

l Hereditary-disease screening

l Chronic-disease pharmacogenomics

l Infectious-disease surveillance

Selected technologies have achieved analytical performance on par with global benchmarks.

Industry Capabilities:

Three wholly-owned subsidiaries secure the entire supply chain:

l Core raw materials & Lab consumables

l IVD reagent manufacturing

l Precision instrumentation & in-vitro diagnostic services.

Build a complete technical service industrial chain, forming a vertical integration of the industrial chain layout. GMP standard production workshop and ISO13485 quality management system to ensure stable product quality. Among them, the core products have been certified by the European Union CE, providing high-quality and traceable diagnostic solutions for global users.

Social Responsibility:

l During the outbreak of African swine fever in 2019, Geneture rapidly developed and supplied relevant diagnostic products, which provided a powerful tool for epidemic control.

l In the face of the global COVID-19 epidemic, Geneture has actively responded to the epidemic by providing nucleic acid extraction reagents and automated detection equipment for more than 20 provincial administrative regions across China and global countries.

Geneture has played an important role in the prevention and control of the epidemic.

Geographic Footprint:

Geneture has established a double cycle pattern of "Domestic + International":

l Domestic: In China, our products cover three application scenarios of hospital clinical, animal husbandry epidemic prevention and scientific research and testing, and has served many domestic hospitals, and carried out in-depth cooperation in Independent Clinical Laboratory.

l International: Geneture has covered more than 60 countries and regions such as the UK, Switzerland, France, South Korea, Southeast Asia, South America, Africa and the Middle East. Our business continues to expand brand influence and market share increase year by year.

Vision:

We adhere to innovation as the driving force, quality as the vitality, service as the core competitiveness, committed to the accuracy and accessibility of life science research and clinical diagnosis, making “Easier diagnosis” to provide beneficial support for the health of all mankind.